Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.38 |
| ▸ | TK1 | P04183 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23487511 | 0.86 | MEN1 (0.46) | MEN1TSHRKMT2AKDM4ETK1 | |
| SCHEMBL20833449 | 0.79 | KDM4E (0.39) | MEN1TSHRKMT2AKDM4EHPRT1 | |
| SCHEMBL20833441 | 0.79 | KDM4E (0.39) | MEN1TSHRKMT2AKDM4EHPRT1 | |
| SCHEMBL25584347 | 0.78 | KDM4E (0.49) | MEN1TSHRKMT2AKDM4EHPRT1 | |
| SCHEMBL25781533 | 0.76 | TK1 (0.58) | MEN1TSHRKMT2AKDM4ETK1 | |
| SCHEMBL22571148 | 0.76 | MEN1 (0.52) | MEN1TSHRKMT2AKDM4ETK1 | |
| SCHEMBL22399456 | 0.75 | MEN1 (0.44) | MEN1TSHRKMT2AKDM4ETK1 | |
| SCHEMBL29832453 | 0.75 | TK1 (0.49) | MEN1TSHRKMT2AKDM4ETK1 | |
| SCHEMBL3457921 | 0.74 | MEN1 (0.50) | MEN1TSHRKMT2AKDM4ETK1 | |
| SCHEMBL16310639 | 0.74 | MEN1 (0.42) | MEN1TSHRKMT2AKDM4EHPRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210015915-A1 | STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210015915-A1 | STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING | STING1, CGAS, TBK1 | MEN1 1520/4885TSHR 3670/4885KMT2A 3236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.